Preparation method of nebivolol and its intermediate compound

A compound and mixed solvent technology, applied in the field of drug synthesis, can solve the problems of high cost, unsuitable for industrial production, low yield, etc.

Active Publication Date: 2014-07-09
福安药业集团重庆博圣制药有限公司 +2
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] To sum up, it is particularly important to improve the problems of long route, l

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of nebivolol and its intermediate compound
  • Preparation method of nebivolol and its intermediate compound
  • Preparation method of nebivolol and its intermediate compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Example 1: Preparation of (R, R)-Compound I and (S, R)-Compound I

[0077] Absolute configuration of 1-[6-fluoro-(2R)-3,4-dihydro-2H-2-benzopyran-4-one]-(1R)-1,2 was obtained by referring to the method disclosed in WO2004041805 -Ethylene glycol, decarbonylation in trifluoroacetic acid / triethylsilane system to give 1-[6-fluoro-(2R)-3,4-dihydro-2H-2-benzopyran]-(1R) -1,2-ethylene glycol. Add 240g of it into 3L of dichloromethane, stir evenly, add 520mL of pyridine, immediately dissolve and clear, cool in an ice-water bath; weigh 236g of p-toluenesulfonyl chloride, add it into a constant pressure funnel, add 800mL of dichloromethane into the constant pressure funnel, It can dissolve completely and form a suspension. Add the suspension dropwise to the reaction bottle under an ice-water bath. After the addition is complete, remove the ice bath and stir at room temperature for 2 days. After the reaction is complete, pour the reaction solution into 3L of water. , stirred and...

Embodiment 2

[0079] Example 2 Preparation of 6-fluoro-(2S)-2-[1-hydroxyl-2-phthalimide-(1R)-ethyl]-3,4-dihydrochroman (S, R) - compound III

[0080] Put 133.2 grams (0.5mol) of S, R-compound I, 166.7 grams (0.9mol) of phthalimide potassium salt (compound II) and 138.2 grams (1.0mol) of anhydrous potassium carbonate into 480ml of DMF, Stir and heat up to 60-70°C, react for 8-10h. Cool to room temperature, add 1200ml of water and stir for 30min, cool to 5°C and filter, rinse the filter cake with 150ml of cold methanol, and dry under reduced pressure to constant weight to obtain compound 146.8g (S,R)-compound III, yield 86%. 1 H-NMR (CDCl 3 ): δ1.86-2.10(m,2H),2.78-2.95(m,2H),3.76-3.82(m,1H),3.86-3.98(m,2H),4.36(m,1H),4.90(d ,1H),6.78(d,1H),6.96-6.98(d,1H),7.01-7.04(d,1H),7.86-7.90(d,2H),7.98-8.02(d,2H),C 19 h 16 NFO 4 HRMS theoretical value 341.3330, measured value 341.3325

Embodiment 3

[0081] Example 3 Preparation of 6-fluoro-(2R)-2-[1-hydroxyl-2-phthalimide-(1R)-ethyl]-3,4-dihydrobenzopyran (R, R) - compound III

[0082] Put 133.2 grams (0.5mol) of R,R-compound I, 166.7 grams (0.9mol) of phthalimide potassium salt (compound II) and 138 grams (1.0mol) of anhydrous potassium carbonate into 480ml of DMF, Stir and heat up to 60-70°C, react for 8-10h. Cool to room temperature, add 1200ml of water and stir for 30min, cool to 5°C and filter, rinse the filter cake with 150ml of cold methanol, and dry under reduced pressure to constant weight to obtain compound 146.5g (R,R)-compound III, yield 85.8%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method of nebivolol used for preparing medicines for treating hypertension of slight or medium degrees, and an intermediate compound. The preparation method comprises the following steps: taking 6-fluoro-2-(1-hydroxy-2-paratoluensulfonyl oxygroup-ethyl)-3,4-dihydrobenzopyrans as an initial raw material, introducing amino, then coupling with 6- fluoro-3,4-dihydro-2-epoxy ethyl-2H-1-benzopyran, and preparing (S,R,R,R) and (R,S,S,S)-nebivolol. Compared with a prior art, the preparation method has the advantages of novel design, simple operation and high yield, the usage of hazardous reagent such as ssodium azide and sodium hydride can be avoided, a column chromatography purifying method is avoided, so that the preparation method conforms to industrial production.

Description

technical field [0001] The invention belongs to the technical field of drug synthesis, and in particular relates to a preparation method of nebivolol, a drug for treating mild to moderate hypertension, and an intermediate compound thereof. Background technique [0002] Nebivolol hydrochloride, chemical name α,α'-[iminobis(methylene)bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2 -methanol)] hydrochloride (structure shown in the following formula), developed by Johnson & Johnson Company of the United States, first listed in Germany and the Netherlands in 1997, for the treatment of essential hypertension, is a cardioselective drug with vasodilator effect Beta-receptor blockers have remarkable curative effect, are convenient to take, and have few adverse reactions. The commercial name of the tablet is Nebilet. [0003] [0004] Nebivolol has 4 chiral centers, and there are 10 isomers in total due to the symmetry of the structure. Its medicinal uses are (S,R,R,R)-form and (R,S,S...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D311/58C07D405/06
CPCC07D311/58C07D405/06
Inventor 梁杰张稳稳李佩杰郭子维洪荣川陈小勇
Owner 福安药业集团重庆博圣制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap